Three of these studies demonstrated that CSF GFAP levels were increased in PMS compared with RRMS [77,78,79,80,81,82], indicating GFAP as a potential biomarker of disease progression in RRMS patients. The gene discussed is GFAP; the disease is relapsing-remitting multiple sclerosis.